Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06809673

PA.RI.GE. Study. The Prognostic Role of Inflammatory Circulating Biomarkers in HNSCC: a Prospective Multicentric Trial

This is a clinical, observational, non-pharmacological, multicenter, prospective case-control no-profit study to assess the prognostic role of several circulating inflammatory biomarkers

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCCS Policlinico San Martino

Genoa, 16132, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years;
  • Written informed consent;
  • Squamous carcinoma of the hypopharynx, larynx and oral cavity;
  • Clinical stage I-IVa according to the VIII edition of AJCC staging system
  • Primary surgery as first line curative intent treatment, followed by ± adjuvant radiotherapy± chemotherapy based on the pathological findings following the NCCN guidelines

Exclusion criteria

  • Relapsing or metastatic disease
  • Locally advanced disease not amenable to curative intent treatment
  • Previous local or systemic treatment for head and neck cancer
  • Previous malignancies (exluding non-melanoma skin cancers) unless complete remission has been achieved at least 5 years before entering the study
  • Psychiatric disorder or known substance abuse
  • Concomitant immunosuppressive treatment
  • Concomitant immunostimulant treatment
  • Chronic inflammatory disease
  • Autoimmune disease
  • Major surgery in the previous year
  • History of recent onset of any condition which, in the investigator's opinion, could interfere with patient adherence for the entire duration of the protocol.
  • Positive serum pregnancy test for women of childbearing age. Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal.

Treatment and study plan

Blood sampling

Other

blood sampling at baseline, 1,3,6 months after surgery and eventually when recurrence is detected.

If adjuvant treatment is planned, blood sampling at baseline, 1 month after surgery, 1,3,6 months after the last fraction of RT and eventually when recurrence is detected.

Primary outcomes

  1. To identify a profile of circulating biomarkers in patients affected by HNSCC

    Time frame: 72 months

  2. To identify a subset of patients in which biomarkers modifications might anticipate disease recurrence

    Time frame: 72 months

Sponsors and collaborators

Lead sponsor

Ospedale Policlinico San Martino

Other

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2029
First posted
Feb 5, 2025
Registry last updated
Feb 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.